EUVIMEDEUVIMED entdecken
Crossref

Giant prolactinoma in Asian-Indians: A single-center experience from Western India

Sandeep Kumar, Saba Samad Memon, Anurag Ranjan Lila, Vijaya Sarathi, Manjeetkaur Sehemby, Manjiri Karlekar, Shilpa Sankhe, Hemangini Thakkar, Virendra A Patil, Nalini Shah, Tushar Bandgar

Annales d'Endocrinologie · 2023

DOI: 10.1016/j.ando.2023.10.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annales d'Endocrinologie, 2023. Verfasst von Sandeep Kumar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Seth G.S. Medical College & King Edward Memorial Hospital, Mumbai, India. Hauptthemen laut MEDLINE: Prolactinoma, Pituitary Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Giant prolactinomas (GP) are rare tumors accounting for 4.3% of prolactinomas, with paucity of literature from India. We aim to describe clinical, biochemical, radiological, and treatment outcomes in a large series of Asian-Indian patients with GP. METHODS: A single-center retrospective analysis of GPs (n=84), age-based (adults: 66 versus pediatric: 18) and gender-based (males: 64 versus females: 20) comparison was done. RESULTS: The mean age at presentation was 34.1±13years, and 64 (76.2%) were males. Males were younger at presentation (32.1±12.2 versus 40.1±13.8years, P: 0.01). The majority presented with mass-effect-related manifestations (visual disturbances: 91.6%, headache: 84.5%) and/or hypogonadism (98.7%). At baseline, largest tumor dimension was 5.3±1.0cm, and serum prolactin was 8343 (3865.5-12,306) ng/mL; most (94.6%) had gonadal axis involvement. Dopamine-agonist (DA) as first-line therapy (45/67, 67.2%) achieved normoprolactinemia (maximum cabergoline dose: 2.0±1.2mg/week) in 36/45 (80%) and tumor response (≥50% reduction) in 36/37 (97.3%) patients at the last follow-up (median duration: 33 [14.5-53.5]months). Notably, gonadal axis recovery was poor (6/30, 20%) despite normoprolactinemia post-DA monotherapy. At latest follow-up, secondary hypothyroidism (32.5% versus 82.6%, P: 0.001) and central hypocortisolism (5.6% versus 42.9%, P: 0.007) were less frequent in DA monotherapy (n=43) than in multimodal therapy group (n=23). The proportion of males (94.4% versus 71.2%, P: 0.04) was higher in the pediatric age group, with DA-induced (first-line) normoprolactinemia observed in 66.7% of them. CONCLUSION: GP has male predominance, DA as first-line therapy normalized prolactin in four-fifths of patients with better preservation of HPT and HPA axes in patients with DA monotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProlactinomaPituitary NeoplasmsAdultFemaleHumansMaleChildRetrospective StudiesProlactinErgolinesDopamine Agonists

Stichwörter der Autor:innen

Dopamine-agonistGiant prolactinomaMacroprolactinomaPituitary adenomaProlactinoma

Substanzen

ProlactinErgolinesDopamine Agonists

Autor:innen und Institutionen

  • Department of Endocrinology, Seth G.S. Medical College & King Edward Memorial Hospital, Mumbai, India.
  • Department of Endocrinology, Vydehi Institute of Medical Sciences, Research Centre, Bangalore, India.
  • Department of Radiology, Seth G.S. Medical College & King Edward Memorial Hospital, Mumbai, India.
  • Department of Endocrinology, Seth G.S. Medical College & King Edward Memorial Hospital, Mumbai, India. Electronic address: drtusharb@gmail.com.

Zitieren

APA

Kumar, S., Memon, S. S., Lila, A. R., Sarathi, V., Sehemby, M., Karlekar, M., Sankhe, S., Thakkar, H., Patil, V. A., Shah, N., & Bandgar, T. (2023). Giant prolactinoma in Asian-Indians: A single-center experience from Western India. Annales d'Endocrinologie. https://doi.org/10.1016/j.ando.2023.10.005

Vancouver

Kumar S, Memon SS, Lila AR, Sarathi V, Sehemby M, Karlekar M, et al. Giant prolactinoma in Asian-Indians: A single-center experience from Western India. Annales d'Endocrinologie. 2023. doi:10.1016/j.ando.2023.10.005

BibTeX
@article{Kumar2023,
  author = {Kumar, Sandeep and Memon, Saba Samad and Lila, Anurag Ranjan and Sarathi, Vijaya and Sehemby, Manjeetkaur and Karlekar, Manjiri and Sankhe, Shilpa and Thakkar, Hemangini and Patil, Virendra A and Shah, Nalini and Bandgar, Tushar},
  title = {Giant prolactinoma in Asian-Indians: A single-center experience from Western India},
  journal = {Annales d'Endocrinologie},
  year = {2023},
  doi = {10.1016/j.ando.2023.10.005}
}
Kostenlos starten →